662,997 Shares in Insmed Incorporated (NASDAQ:INSM) Bought by Brown Advisory Inc.

Brown Advisory Inc. bought a new stake in Insmed Incorporated (NASDAQ:INSM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 662,997 shares of the biopharmaceutical company's stock, valued at approximately $45,773,000. Brown Advisory Inc. owned 0.37% of Insmed as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Tidal Investments LLC boosted its holdings in Insmed by 447.0% during the third quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company's stock worth $1,759,000 after buying an additional 19,696 shares in the last quarter. Principal Financial Group Inc. increased its stake in Insmed by 12.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock valued at $136,648,000 after purchasing an additional 214,130 shares in the last quarter. Everence Capital Management Inc. purchased a new position in Insmed in the 4th quarter valued at approximately $352,000. Harbor Capital Advisors Inc. raised its holdings in Insmed by 237.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company's stock worth $4,115,000 after purchasing an additional 41,918 shares during the last quarter. Finally, JCIC Asset Management Inc. boosted its position in Insmed by 40.7% during the fourth quarter. JCIC Asset Management Inc. now owns 2,560 shares of the biopharmaceutical company's stock worth $177,000 after purchasing an additional 740 shares in the last quarter.

Wall Street Analysts Forecast Growth

INSM has been the subject of several research reports. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 price target on shares of Insmed in a research note on Wednesday, March 19th. Wells Fargo & Company lifted their target price on shares of Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 19th. UBS Group reduced their price target on shares of Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday. Bank of America raised their price objective on shares of Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research note on Thursday, March 20th. Finally, Morgan Stanley upped their target price on Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $93.93.

Insmed Trading Down 0.8 %

INSM stock traded down $0.55 on Friday, hitting $65.08. 2,388,354 shares of the company were exchanged, compared to its average volume of 2,324,735. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market capitalization of $11.83 billion, a price-to-earnings ratio of -11.64 and a beta of 0.84. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The business's fifty day moving average is $72.61 and its two-hundred day moving average is $73.32.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company's quarterly revenue was up 22.9% compared to the same quarter last year. During the same period last year, the business posted ($1.06) earnings per share. As a group, research analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Buying and Selling at Insmed

In other Insmed news, COO Roger Adsett sold 42,975 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $78.61, for a total transaction of $3,378,264.75. Following the transaction, the chief operating officer now owns 146,082 shares in the company, valued at $11,483,506.02. The trade was a 22.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Martina M.D. Flammer sold 37,828 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $78.61, for a total value of $2,973,659.08. Following the completion of the sale, the insider now owns 100,165 shares of the company's stock, valued at approximately $7,873,970.65. This trade represents a 27.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 182,337 shares of company stock valued at $14,284,557 over the last ninety days. Corporate insiders own 3.00% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.